{"id":"W4320717208","doi":"10.1159/000529636","title":"Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial","year":2023,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Bayer Yakuhin; Chugai Pharmaceutical; Sirtex Medical; Ipsen; Servier; Ono Pharmaceutical; Eisai; Sanofi; Bayer HealthCare; Incyte; EA Pharma Co., Ltd.; Gilead Sciences; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Hepatocellular carcinoma; Term (time); Oncology; Internal medicine; Cancer; Immunotherapy; Physics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005808386,0.001036542,0.001941777,0.0002344222,0.0004636275,0.001565614,0.0005478185,0.001228114,0.005205329],"category_scores_gemma":[0.00292388,0.0003305281,0.002885903,0.0004736326,0.0004345537,0.001019966,0.0005404472,0.002816143,0.001024222],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008347239,"about_ca_system_score_gemma":0.0008950172,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006758229,"about_ca_topic_score_gemma":0.001405417,"domain_scores_codex":[0.9987524,0.0006940599,0.00008681315,0.0001616534,0.0001345897,0.0001706017],"domain_scores_gemma":[0.9980258,0.0004587926,0.0006402791,0.0002566761,0.0001769521,0.0004415977],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9174783,0.002680046,0.004928156,0.00173842,0.006288311,0.0002005999,0.0001137811,0.001303925,0.004563342,0.0002230706,0.007493793,0.05298817],"study_design_scores_gemma":[0.8402644,0.08557177,0.04758469,0.0005056655,0.009712051,0.0006379948,0.00008094208,0.001107369,0.002163694,0.0008046257,0.01148153,0.00008528081],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9465497,0.03140183,0.001467703,0.001867649,0.0004627887,0.002192245,0.01021735,0.0001508174,0.005690099],"genre_scores_gemma":[0.9709599,0.006372266,0.001019735,0.002043406,0.0004464205,0.002467655,0.01393345,0.00004629873,0.002710892],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005808386,"threshold_uncertainty_score":0.03071803,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09416067897063918,"score_gpt":0.321198574962859,"score_spread":0.2270378959922199,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}